Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07553442
PHASE2

A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran

Sponsor: Alnylam Pharmaceuticals

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.

Official title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Single Dose Study of the Efficacy, Pharmacodynamics, and Safety of ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

93

Start Date

2026-04-27

Completion Date

2028-10-01

Last Updated

2026-05-14

Healthy Volunteers

No

Conditions

Interventions

DRUG

ALN-AGT01 RVR

ALN-AGT01 RVR will be administered subcutaneously (SC)

DRUG

Placebo

Placebo will be administered SC

DRUG

Zilebesiran

Zilebesiran will be administered SC

Locations (3)

Clinical Trial Site

Lake Forest, California, United States

Clinical Trial Site

Tampa, Florida, United States

Clinical Trial Site

Savannah, Georgia, United States